LU92017I2 - Une combinaison de produit comprenant de l'aspirine et de l'ésoméprazole (magnésium trihydrate). - Google Patents

Une combinaison de produit comprenant de l'aspirine et de l'ésoméprazole (magnésium trihydrate).

Info

Publication number
LU92017I2
LU92017I2 LU92017C LU92017C LU92017I2 LU 92017 I2 LU92017 I2 LU 92017I2 LU 92017 C LU92017 C LU 92017C LU 92017 C LU92017 C LU 92017C LU 92017 I2 LU92017 I2 LU 92017I2
Authority
LU
Luxembourg
Prior art keywords
esomeprazole
aspirin
product combination
magnesium trihydrate
trihydrate
Prior art date
Application number
LU92017C
Other languages
English (en)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20407186&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU92017(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LU92017I2 publication Critical patent/LU92017I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
LU92017C 1997-05-30 2012-06-06 Une combinaison de produit comprenant de l'aspirine et de l'ésoméprazole (magnésium trihydrate). LU92017I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9702065A SE510650C2 (sv) 1997-05-30 1997-05-30 Ny förening
PCT/SE1998/000974 WO1998054171A1 (fr) 1997-05-30 1998-05-25 Nouvelle forme de s-omeprazole

Publications (1)

Publication Number Publication Date
LU92017I2 true LU92017I2 (fr) 2012-08-06

Family

ID=20407186

Family Applications (2)

Application Number Title Priority Date Filing Date
LU91871C LU91871I2 (fr) 1997-05-30 2011-09-19 Une combinaison de produit comprenant du naproxèneet de l'ésoméprazole (magnésium trihydrate)
LU92017C LU92017I2 (fr) 1997-05-30 2012-06-06 Une combinaison de produit comprenant de l'aspirine et de l'ésoméprazole (magnésium trihydrate).

Family Applications Before (1)

Application Number Title Priority Date Filing Date
LU91871C LU91871I2 (fr) 1997-05-30 2011-09-19 Une combinaison de produit comprenant du naproxèneet de l'ésoméprazole (magnésium trihydrate)

Country Status (44)

Country Link
US (6) US6369085B1 (fr)
EP (2) EP1273581B1 (fr)
JP (2) JP4002303B2 (fr)
KR (2) KR100527804B1 (fr)
CN (1) CN1161351C (fr)
AR (2) AR012717A1 (fr)
AT (2) ATE239011T1 (fr)
AU (1) AU722839B2 (fr)
BR (1) BR9809509A (fr)
CA (2) CA2521391C (fr)
CY (1) CY2012029I2 (fr)
CZ (1) CZ297585B6 (fr)
DE (3) DE69829511T2 (fr)
DK (2) DK1273581T3 (fr)
DZ (1) DZ2495A1 (fr)
EE (1) EE03875B1 (fr)
EG (1) EG24291A (fr)
ES (2) ES2195345T7 (fr)
HK (2) HK1051681A1 (fr)
HR (1) HRP980263B1 (fr)
HU (1) HU225987B1 (fr)
ID (1) ID29306A (fr)
IL (1) IL132947A0 (fr)
IS (2) IS2142B (fr)
LU (2) LU91871I2 (fr)
MA (1) MA26500A1 (fr)
ME (3) ME00198B (fr)
MY (2) MY120745A (fr)
NO (3) NO317518B1 (fr)
NZ (1) NZ500991A (fr)
PL (1) PL193546B1 (fr)
PT (2) PT984957E (fr)
RS (2) RS50067B (fr)
RU (1) RU2184115C2 (fr)
SA (2) SA98190280B1 (fr)
SE (1) SE510650C2 (fr)
SI (2) SI0984957T1 (fr)
SK (2) SK284837B6 (fr)
TN (1) TNSN98074A1 (fr)
TR (1) TR199902934T2 (fr)
TW (1) TW538040B (fr)
UA (1) UA60334C2 (fr)
WO (1) WO1998054171A1 (fr)
ZA (1) ZA984179B (fr)

Families Citing this family (110)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6875872B1 (en) * 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
ES2283012T3 (es) 1996-01-04 2007-10-16 Novartis Vaccines And Diagnostics, Inc. Bacterioferritina de helicobacter pylori.
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6699885B2 (en) * 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
SE9900274D0 (sv) * 1999-01-28 1999-01-28 Astra Ab New compound
US6369087B1 (en) * 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
US7345061B2 (en) * 2002-03-05 2008-03-18 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
AU2003262375A1 (en) * 2002-04-22 2003-11-03 Sun Pharmaceutical Industries Limited Optically active substituted pyridinylmethyl-sulphinyl-benzimidazole and salts
EP1515963B1 (fr) * 2002-06-27 2007-02-14 Dr. Reddy's Laboratories Ltd. Procede de preparation de composes sulfoxyde optiquement purs ou optiquement enrichis, notamment de l'esomeprazole amorphe et ses sels
ATE353887T1 (de) * 2002-06-27 2007-03-15 Reddys Lab Ltd Dr Verfahren zur herstellung optisch reiner oder optisch angereicherter sulfoxidverbindungen einschliesslich amorphen esomeprazols und dessen salze
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
CA2501424A1 (fr) * 2002-08-30 2004-03-11 Dr. Reddy's Laboratories Limited Hydrates amorphes d'esomeprazole magnesium et leur procede de preparation
WO2004035052A1 (fr) 2002-10-16 2004-04-29 Takeda Pharmaceutical Company Limited Preparations solides stables
EP1556043A1 (fr) * 2002-10-22 2005-07-27 Ranbaxy Laboratories, Ltd. Forme amorphe de sels d'esomeprazole
US20040242642A1 (en) * 2002-11-18 2004-12-02 Dr. Reddy's Laboratories Limited Crystalline esomeprazole compounds and process for the preparation thereof
EP1583507A2 (fr) * 2003-01-07 2005-10-12 Ranbaxy Laboratories Limited Sels de magnesium de derives de l'imidazole
AU2003238671A1 (en) * 2003-04-10 2004-11-01 Hetero Drugs Limitd Novel crystalline forms of s-omeprazole magnesium
US20070060556A1 (en) 2003-05-05 2007-03-15 Yatendra Kumar Barium salt of benzimidazole derivative
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
AR046400A1 (es) * 2003-07-23 2005-12-07 Altana Pharma Ag Sales de pantoprazol
CN100457104C (zh) * 2003-07-23 2009-02-04 尼科梅德有限责任公司 质子泵抑制剂的碱性盐
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
EP1715861A2 (fr) * 2004-02-18 2006-11-02 Allergan, Inc. Methodes et compositions d'administration de promedicaments d'inhibiteurs de la pompe a protons
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
CA2561700A1 (fr) * 2004-04-16 2005-12-15 Santarus, Inc. Combinaison d'un inhibiteur de la pompe a protons, d'un agent tampon et d'un agent prokinetique
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267159A1 (en) * 2004-05-28 2005-12-01 Aaipharma, Inc. Magnesium complexes of S-omeprazole
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
JP5457632B2 (ja) * 2004-06-24 2014-04-02 アストラゼネカ・アクチエボラーグ エソメプラゾールのナトリウム塩の製造に使用するための結晶の改変型の作成方法
ES2246149B1 (es) 2004-07-02 2007-06-01 Esteve Quimica, S.A. Formas solidas de la sal magnesica de s-omeprazol y procedimientos para su preparacion.
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
WO2006073779A1 (fr) * 2004-12-30 2006-07-13 Transform Phamaceuticals, Inc. Nouvelles formes de l'omeprazole et méthodes correspondantes
ES2259269B1 (es) 2005-03-03 2007-11-01 Esteve Quimica, S.A. Procedimiento para la preparacion de derivados de 2-(2-piridilmetilsulfinil)-bencimidazol opticamente activos.
US20060210637A1 (en) * 2005-03-17 2006-09-21 Qpharma, Llc Stable tablet dosage forms of proton pump inhibitors
RU2007145207A (ru) * 2005-05-06 2009-06-20 Гленмарк Фармасьютикалз Лимитед (In) Стронциваемая соль эзомепразола, способ ее получения и содержащее ее фармацевтические композиции
EP1891043A1 (fr) * 2005-06-15 2008-02-27 Hetero Drugs Limited Ésoméprazole hydraté amorphe
EP1904064A4 (fr) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr Omeprazole de forme b
KR100641534B1 (ko) 2005-07-28 2006-11-01 한미약품 주식회사 에스오메프라졸 및 그의 염의 제조방법
US20070026071A1 (en) * 2005-07-28 2007-02-01 Qpharma, Llc Magnesium salt proton pump inhibitor dosage forms
WO2007031845A2 (fr) * 2005-09-14 2007-03-22 Glenmark Pharmaceuticals Limited Formes polymorphiques de sels de magnesium de (s)-omeprazole et procedes de preparation desdites formes
EP1934201A1 (fr) * 2005-10-06 2008-06-25 Auspex Pharmaceuticals Inc. Inhibiteurs deutériés d'atpase h+,k+ gastrique ayant des propriétés thérapeutiques renforcées
WO2007049914A1 (fr) * 2005-10-26 2007-05-03 Hanmi Pharm. Co., Ltd. S-omeprazole strontium ou hydrate de ce composé, méthode de synthèse et préparation pharmaceutique le comprenant
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
EP1801110A1 (fr) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Sel d'arginine d'ésoméprazole
US7553857B2 (en) * 2005-12-23 2009-06-30 Lek Pharmaceuticals D.D. S-omeprazole magnesium
CN100384839C (zh) * 2006-02-17 2008-04-30 中国科学院上海有机化学研究所 [(取代的吡啶基)甲基]亚磺酰基-1h-苯并咪唑类化合物及其对映体的锌盐的制备方法
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
US8063074B2 (en) 2006-05-04 2011-11-22 Dr. Reddy's Laboratories Limited Polymorphic forms of esomeprazole sodium
WO2007148213A2 (fr) * 2006-06-21 2007-12-27 Glenmark Pharmaceuticals Limited Nouveau polymorphe de potassium d'ésoméprazole
CA2665226C (fr) 2006-10-05 2014-05-13 Santarus, Inc. Nouvelles formulations pour une liberation immediate d'inhibiteurs de pompe a protons et procedes d'utilisation de ces formulations
EP2486910A3 (fr) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Appareil comprenant plusieurs chambres et une tête de distribution
EP1947099A1 (fr) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Procédé pour l'élimination de solvant des sels d'oméprazole
EA200900985A1 (ru) 2007-01-31 2009-12-30 Крка, Товарна Здравил, Д. Д., Ново Место Способ получения оптически чистого омепразола
CA2678702A1 (fr) 2007-02-21 2008-08-28 Cipla Limited Procede pour la preparation de esomeprazole magnesium dihydrate
KR101303813B1 (ko) * 2007-04-16 2013-09-04 에스케이케미칼주식회사 라세믹 오메프라졸로부터 에스오메프라졸의 개선된제조방법
EP2000468A1 (fr) 2007-05-09 2008-12-10 Dr. Reddy's Laboratories Ltd. Sels d'ésoméprazole et procédés pour leur préparation
EP2152691B1 (fr) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited Procédé amélioré pour préparer un inhibiteur de la pompe à protons optiquement actif
FR2920428B1 (fr) * 2007-08-29 2012-06-15 Univ Rouen Procede de dedoublement de sels de l'omeprazole
US8106210B2 (en) * 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
AU2008310735B2 (en) 2007-10-12 2013-09-12 Takeda Pharmaceutical Company Limited Methods of treating gastrointestinal disorders independent of the intake of food
WO2009074997A2 (fr) * 2007-12-10 2009-06-18 Lee Pharma Ltd. Nouveau procédé de préparation de sel de magnésium cristallin de (s)-oméprazole dihydraté
EP2240496A4 (fr) * 2008-02-01 2011-05-11 Reddys Lab Ltd Dr Préparation de magnésium d ésoméprazole et de ses hydrates
WO2009137648A1 (fr) * 2008-05-09 2009-11-12 Aptapharma, Inc. Pastilles multicouches inhibant la pompe à protons
US20090280173A1 (en) * 2008-05-09 2009-11-12 Ishwar Chauhan Multilayer Omeprazole Tablets
EP2143722A1 (fr) 2008-07-09 2010-01-13 Lek Pharmaceuticals D.D. Procédé de préparation de sodium ésoméprazole de haute pureté chimique et nouvelles formes de sodium ésoméprazole
EP2147918A1 (fr) * 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Procédé de préparation de magnésium d'oméprazole S dans une forme stable
EP2344139A1 (fr) 2008-09-09 2011-07-20 AstraZeneca AB Procédé d'administration d'une composition pharmaceutique à un patient en ayant besoin
CN101391993B (zh) * 2008-10-28 2012-07-04 安徽美诺华药物化学有限公司 通过与(s)-(-)-1,1'-联萘-2,2'-二酚形成包合配合物制备s-奥美拉唑及其盐的方法
WO2010097583A1 (fr) 2009-02-24 2010-09-02 Cipla Limited Polymorphe de l'ésoméprazole de potassium et sa préparation
US20100267959A1 (en) * 2009-04-15 2010-10-21 Glenmark Generics Limited Process for the preparation of esomeprazole magnesium dihydrate
WO2010122583A2 (fr) 2009-04-24 2010-10-28 Rubicon Research Private Limited Compositions pharmaceutiques orales comprenant des substances labiles en milieu acide
US20130030186A1 (en) * 2009-06-02 2013-01-31 Sun Pharmaceutical Industries Limited Process for preparing sulphoxide compounds
WO2010151697A1 (fr) * 2009-06-25 2010-12-29 Pozen Inc. Procédé de traitement d'un patient nécessitant une thérapie à l'aspirine
JP2012531409A (ja) 2009-06-25 2012-12-10 アストラゼネカ・アクチエボラーグ Ｎｓａｉｄ関連潰瘍を発症するリスクがある患者の処置方法
WO2011012957A1 (fr) * 2009-07-29 2011-02-03 Orchid Chemicals & Pharmaceuticals Ltd Procédé perfectionné pour la préparation d'ésoméprazole magnésique dihydraté
EP2499125B1 (fr) 2009-11-12 2016-01-27 Hetero Research Foundation Procédé de dédoublement de l'oméprazole
EP2510089B1 (fr) 2009-12-08 2015-10-21 Codexis, Inc. Synthèse de composés prazoles
US20110207779A1 (en) * 2010-02-25 2011-08-25 Glenmark Generics Ltd Process for the preparation of esomeprazole magnesium
FR2959509B1 (fr) 2010-05-03 2012-07-13 Prod Chim Auxiliaires Et De Synthese Phase precurseur et son utilisation pour preparer le sel de magnesium tetrahydrate d'un enantiomere d'omeprazole
CN102241668B (zh) * 2010-05-11 2015-11-25 中国科学院成都有机化学有限公司 S-奥美拉唑盐
WO2012078800A2 (fr) 2010-12-08 2012-06-14 Codexis, Inc. Biocatalyseurs et procédés de synthèse de l'armodafinil
CN102757421A (zh) * 2011-04-29 2012-10-31 江苏正大天晴药业股份有限公司 埃索美拉唑的纯化方法
CN102911158B (zh) * 2011-07-31 2015-07-22 连云港润众制药有限公司 埃索美拉唑镁的晶型
CN102936238B (zh) * 2011-11-25 2015-02-18 成都自豪药业有限公司 S-奥美拉唑镁盐的晶型及其制备方法
WO2013088272A1 (fr) * 2011-12-14 2013-06-20 Wockhardt Limited Composition pharmaceutique comprenant du dihydrate de magnésium d'ésoméprazole
EA028049B1 (ru) 2011-12-28 2017-10-31 Поузен Инк. Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN102993184A (zh) * 2013-01-08 2013-03-27 湖南方盛制药股份有限公司 一种埃索美拉唑及其镁盐三水合物的制备方法
CN104250243B (zh) * 2013-06-27 2016-12-28 四川国为制药有限公司 一种埃索美拉唑镁二水合物a晶型的制备方法
CN103570686B (zh) * 2013-10-14 2015-04-01 哈药集团技术中心 一种埃索美拉唑钠的合成及精制工艺
CN104725357A (zh) * 2013-12-24 2015-06-24 苏州联友制药技术有限公司 一种埃索美拉唑镁二水合物晶型b的制备方法
FR3018812A1 (fr) 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
CN104447699A (zh) * 2014-12-10 2015-03-25 哈药集团技术中心 一种埃索美拉唑镁三水合物的制备方法
CN105111188B (zh) * 2015-08-19 2018-01-19 扬子江药业集团有限公司 一种埃索美拉唑镁三水合物晶型的制备方法
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
CN106397402B (zh) * 2016-08-30 2019-05-03 山东罗欣药业集团股份有限公司 一种埃索美拉唑镁晶型化合物及其制备方法
KR102080023B1 (ko) 2018-01-29 2020-02-21 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 안정한 약제학적 조성물
KR102006777B1 (ko) 2018-01-29 2019-10-08 주식회사 종근당 에스오메프라졸 및 탄산수소나트륨을 포함하는 약제학적 제제
KR102432084B1 (ko) 2021-11-16 2022-08-12 알리코제약(주) S-오메프라졸을 함유하는 안정성이 개선되고 소형화된 정제
WO2024075017A1 (fr) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition de calcification de valve aortique

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
US5244891A (en) * 1985-08-05 1993-09-14 Bristol-Myers Squibb Company Injectable compositions of cefepime dihydrochloride hydrate
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
DE4035455A1 (de) 1990-11-08 1992-05-14 Byk Gulden Lomberg Chem Fab Enantiomerentrennung
US5360582A (en) 1991-07-15 1994-11-01 Minnesota Mining And Manufacturing Company Nonlinear optical materials containing polar disulfone-functionalized molecules
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US5877192A (en) 1993-05-28 1999-03-02 Astra Aktiebolag Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
FR2719045B1 (fr) * 1994-04-20 1996-05-31 Rhone Poulenc Chimie Procédé de préparation d'acide L-aspartique à partir d'aspartate d'ammonium.
FR2722191B1 (fr) * 1994-07-08 1996-08-23 Rhone Poulenc Rorer Sa Procede de preparation du trihydrate du (2r,3s)-3-tertbutoxycarbonylamino-2-hydroxy-3-phenylpropionate de 4-acetoxy2alpha-benzoyloxy-5beta,20epoxy-1,7beta,10beta trihydroxy-9-oxo-tax-11-en-13alpha-yle
US5817338A (en) 1994-07-08 1998-10-06 Astra Aktiebolag Multiple unit tableted dosage form of omeprazole
SE504459C2 (sv) 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
DE69520225T2 (de) * 1994-11-14 2001-10-11 Daiichi Seiyaku Co Verfahren zur Herstellung von 3-[2-[4-(3-Chlor-2-methylphenyl)-1- piperazinyl] ethyl]-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazol-dihydrochlorid-3.5-hydrat.
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
SE9500422D0 (sv) 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
CN1042423C (zh) 1995-05-25 1999-03-10 常州市第四制药厂 奥美拉唑盐水合物及其制备方法
SE9600072D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients II
SE9600071D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) * 1997-05-30 1999-06-14 Astra Ab Ny förening
AR057181A1 (es) 2005-11-30 2007-11-21 Astra Ab Nueva forma de dosificacion de combinacion

Also Published As

Publication number Publication date
CY2012029I1 (el) 2015-08-05
DE69829511D1 (de) 2005-04-28
JP2002501529A (ja) 2002-01-15
DE69814069T3 (de) 2014-03-27
CZ297585B6 (cs) 2007-01-10
CN1258295A (zh) 2000-06-28
MY127793A (en) 2006-12-29
MEP18008A (en) 2010-10-10
KR100527804B1 (ko) 2005-11-15
EE9900550A (et) 2000-06-15
SE9702065D0 (sv) 1997-05-30
PT984957E (pt) 2003-07-31
US20050075369A1 (en) 2005-04-07
EP0984957B3 (fr) 2013-09-18
CA2290963A1 (fr) 1998-12-03
ES2236407T3 (es) 2005-07-16
HK1051681A1 (en) 2003-08-15
IL132947A0 (en) 2001-03-19
AR059589A2 (es) 2008-04-16
HUP0001849A3 (en) 2003-02-28
UA60334C2 (uk) 2003-10-15
ID29306A (id) 2001-08-16
DK1273581T3 (da) 2005-06-06
SE510650C2 (sv) 1999-06-14
HUP0001849A2 (hu) 2002-05-29
HU0001849D0 (fr) 2002-05-29
US20120252847A1 (en) 2012-10-04
ZA984179B (en) 1998-11-30
CA2290963C (fr) 2006-03-28
JP2007161734A (ja) 2007-06-28
BR9809509A (pt) 2000-06-20
TNSN98074A1 (fr) 2005-03-15
NO2011010I1 (no) 2011-06-20
DZ2495A1 (fr) 2003-01-25
NO317518B1 (no) 2004-11-08
SK162599A3 (en) 2000-06-12
EG24291A (en) 2009-01-08
ES2195345T3 (es) 2003-12-01
KR20050042827A (ko) 2005-05-10
IS5272A (is) 1999-11-25
US8466175B2 (en) 2013-06-18
MY120745A (en) 2005-11-30
SK284837B6 (sk) 2005-12-01
PT1273581E (pt) 2005-06-30
SI1273581T1 (fr) 2005-08-31
SK285137B6 (sk) 2006-07-07
DE122012000017I1 (de) 2012-08-16
CY2012029I2 (el) 2015-08-05
KR20010013126A (ko) 2001-02-26
TR199902934T2 (xx) 2000-04-21
EP1273581A1 (fr) 2003-01-08
NO995852L (no) 2000-01-31
US20110130570A1 (en) 2011-06-02
US7745466B2 (en) 2010-06-29
HK1025962A1 (en) 2000-12-01
IS8368A (is) 2006-03-22
CN1161351C (zh) 2004-08-11
AU722839B2 (en) 2000-08-10
HU225987B1 (en) 2008-02-28
MEP24908A (en) 2010-10-10
DE69829511T2 (de) 2006-02-16
HRP980263B1 (en) 2002-02-28
ME00198B (me) 2011-02-10
WO1998054171A8 (fr) 1999-12-23
SI0984957T1 (en) 2003-10-31
US6369085B1 (en) 2002-04-09
US20020198239A1 (en) 2002-12-26
US8076361B2 (en) 2011-12-13
DE69814069T2 (de) 2004-04-01
RS50067B (sr) 2009-01-22
RS20070459A (en) 2008-06-05
RS50005B (sr) 2008-09-29
NZ500991A (en) 2001-05-25
PL337180A1 (en) 2000-08-14
SA05260296B1 (ar) 2008-04-16
JP4002303B2 (ja) 2007-10-31
IS2774B (is) 2012-03-15
HRP980263A2 (en) 1999-02-28
NO995852D0 (no) 1999-11-29
PL193546B1 (pl) 2007-02-28
US7411070B2 (en) 2008-08-12
ATE291574T1 (de) 2005-04-15
IS2142B (is) 2006-09-15
SA98190280B1 (ar) 2006-07-04
WO1998054171A1 (fr) 1998-12-03
YU60999A (sh) 2002-03-18
DK0984957T3 (da) 2003-06-30
CA2521391C (fr) 2009-09-29
EP1273581B1 (fr) 2005-03-23
EE03875B1 (et) 2002-10-15
EP0984957B1 (fr) 2003-05-02
EP0984957A1 (fr) 2000-03-15
ES2195345T7 (es) 2014-01-15
DE69814069D1 (de) 2003-06-05
TW538040B (en) 2003-06-21
US20080255363A1 (en) 2008-10-16
NO2012011I1 (no) 2012-06-18
MA26500A1 (fr) 2004-12-20
ATE239011T1 (de) 2003-05-15
KR100540720B1 (ko) 2006-01-12
SE9702065L (sv) 1998-12-01
RU2184115C2 (ru) 2002-06-27
AU7793598A (en) 1998-12-30
US6677455B2 (en) 2004-01-13
LU91871I2 (fr) 2011-11-21
AR012717A1 (es) 2000-11-08
CA2521391A1 (fr) 1998-12-03

Similar Documents

Publication Publication Date Title
LU92017I2 (fr) Une combinaison de produit comprenant de l'aspirine et de l'ésoméprazole (magnésium trihydrate).
TR199800631A3 (tr) Ecza formülasyonu.
FR2759558B1 (fr) Elements de blocage d'une cage dans un rayonnage
BR9607851B1 (pt) combinaÇço e formulaÇço farmacÊutica.
ID24654A (id) Formulasi farmasi omeprazola
ZA985364B (en) Pharmaceutical formulations containing voriconazole.
ZA967546B (en) Pharmaceutical formulation.
TR199600849A2 (tr) 1alfa-26 dihidroksi -D-homo-vitamin D3.
MX9804661A (es) Mezclas insecticidas sinergicas.
DE69610980T2 (de) Chemische komplexe
NL1002262A1 (nl) Vloerbedekking.
ID25544A (id) Obat tetes mata larut-air
DE29708649U1 (de) Tablettenspender
FR2760614B1 (fr) Presentoir pour journaux ou similaires
DE29509111U1 (de) Verkaufscontainer
DE29706027U1 (de) Sicherheitsprodukt
ZA994697B (en) Pharmaceutical formulation.
ES1037552Y (es) Conjunto dispensador de bolsas.
FR2720911B1 (fr) Caisse d'exposition-malle.
DE29717791U1 (de) Regalkonsole
ZA9810321B (en) 1,4-Diaryl-2,3 Difluoro-2-butene insecticidal and acaricidal agents.
TR199600958A2 (tr) Ayak siyirici.
FR2721426B1 (fr) Tableau d'affichage mural.
FR2710360B1 (fr) Plancher d'exposition démontable.
FR2702821B3 (fr) Console murale.